Insulet (PODD) ZACKS·2024-11-07 23:21Company Performance - Insulet reported quarterly earnings of $0.90 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, and up from $0.71 per share a year ago, representing an earnings surprise of 16.88% [1] - The company posted revenues of $543.9 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.90%, compared to year-ago revenues of $432.7 million [2] - Insulet has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] Stock Outlook - Insulet shares have increased approximately 10.3% since the beginning of the year, while the S&P 500 has gained 24.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.02 on revenues of $564.54 million, and for the current fiscal year, it is $3.04 on revenues of $2.01 billion [7] Industry Context - The Medical - Products industry, to which Insulet belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]